Mesoblast Limited (MESO)

Market Cap	1.43B
Revenue (ttm)	5.67M
Net Income (ttm)	-103.35M
Shares Out	1.15B
EPS (ttm)	-0.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	74,424
Open	11.23
Previous Close	11.05
Day's Range	11.23 - 11.50
52-Week Range	5.78 - 22.00
Beta	2.03
Analysts	Buy
Price Target	18.00 (+57.76%)
Earnings Date	Feb 26, 2025

About MESO

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn’s disease; and Remestemcel-L, whi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 73
• Stock Exchange: NASDAQ
• Ticker Symbol: MESO
• Website: https://www.mesoblast.com

Financial Performance

In 2024, Mesoblast's revenue was $5.90 million, a decrease of -21.32% compared to the previous year's $7.50 million. Losses were -$87.96 million, 7.41% more than in 2023.

Analyst Forecast

According to 4 analysts, the average rating for MESO stock is "Buy." The 12-month stock price forecast is $18.0, which is an increase of 57.76% from the latest price.

Price Target

$18.0

(57.76% upside)

Analyst Consensus: Buy